Literature DB >> 24150218

Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.

T V Kourelis1, S K Kumar1, G Srivastava1, M A Gertz1, M Q Lacy1, F K Buadi1, R A Kyle1, A Dispenzieri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24150218     DOI： 10.1038/leu.2013.300

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

Authors:  Paul G Richardson; Jacob P Laubach; Robert L Schlossman; Irene M Ghobrial; Katherine C Redman; Mary McKenney; Diane Warren; Kimberly Noonan; Laura Lunde; Deborah Doss; Kathleen Colson; Teru Hideshima; Constantine Mitsiades; Nikhil C Munshi; Kenneth C Anderson
Journal:  Eur J Haematol       Date:  2012-03-07       Impact factor: 2.997

2.  Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.

Authors:  M Boccadoro; F Marmont; M Tribalto; G Fossati; V Redoglia; S Battaglio; M Massaia; A Gallamini; B Comotti; T Barbui
Journal:  J Clin Oncol       Date:  1989-01       Impact factor: 44.544

3.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Authors:  Joseph R Mikhael; David Dingli; Vivek Roy; Craig B Reeder; Francis K Buadi; Suzanne R Hayman; Angela Dispenzieri; Rafael Fonseca; Taimur Sher; Robert A Kyle; Yi Lin; Stephen J Russell; Shaji Kumar; P Leif Bergsagel; Steven R Zeldenrust; Nelson Leung; Matthew T Drake; Prashant Kapoor; Stephen M Ansell; Thomas E Witzig; John A Lust; Robert J Dalton; Morie A Gertz; A Keith Stewart; Keith Stewart; S Vincent Rajkumar; Asher Chanan-Khan; Martha Q Lacy
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

4.  Relationship between depth of response and outcome in multiple myeloma.

Authors:  David Dingli; Jorge M Pacheco; Grzegorz S Nowakowski; Shaji K Kumar; Angela Dispenzieri; Suzanne R Hayman; Martha Q Lacy; Dennis A Gastineau; Morie A Gertz
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

5.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

Review 6.  Treatment of plasma cell dyscrasias with lenalidomide.

Authors:  M A Dimopoulos; E Kastritis; S V Rajkumar
Journal:  Leukemia       Date:  2008-05-29       Impact factor: 11.528

7.  Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.

Authors:  G Srivastava; V Rana; M Q Lacy; F K Buadi; S R Hayman; A Dispenzieri; M A Gertz; D Dingli; S Zeldenrust; S Russell; A McCurdy; P Kapoor; R Kyle; S V Rajkumar; S Kumar
Journal:  Leukemia       Date:  2013-05-07       Impact factor: 11.528

8.  High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.

Authors:  Frits van Rhee; Vanessa Bolejack; Klaus Hollmig; Mauricio Pineda-Roman; Elias Anaissie; Joshua Epstein; John D Shaughnessy; Maurizio Zangari; Guido Tricot; Abid Mohiuddin; Yazan Alsayed; Gail Woods; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2007-04-06       Impact factor: 22.113
  8 in total
  1 in total

Review 1.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.